Targeting PPARγ acetylation to prevent and treat type 2 diabetes
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment
Researchers are developing a new type of medicine that aims to improve insulin sensitivity without the weight gain and heart problems linked to older diabetes drugs, for people with or at high risk for type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11240026 on NIH RePORTER |
What this research studies
From a patient's perspective, the team is testing a new class of compounds that block a specific chemical change (acetylation) on the PPARγ protein that controls how fat and sugar are handled in the body. They will use lab-grown cells and animal models to see whether these compounds keep the good blood-sugar benefits while avoiding the weight gain and heart risks seen with older PPARγ drugs. The work focuses on a lead compound class (including TPMD) and studies how the drug changes PPARγ activity and metabolic outcomes in preclinical models. Positive results would support moving toward clinical trials in people with obesity-linked insulin resistance or type 2 diabetes.
Who could benefit from this research
Good fit: Ideal candidates for eventual trials would be adults with obesity-linked insulin resistance or type 2 diabetes, especially those who cannot tolerate existing PPARγ-activating drugs.
Not a fit: People with type 1 diabetes or metabolic problems not driven by insulin resistance are unlikely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this approach could give people with or at risk for type 2 diabetes a safer way to improve insulin sensitivity without major weight gain or heart-related side effects.
How similar studies have performed: Older PPARγ-activating drugs (TZDs) improved insulin sensitivity but caused weight gain and heart risks, and while targeting PPARγ modifications is a promising and newer idea, it has shown mainly preclinical promise and not yet proven in humans.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Wang, Weidong — University of Alabama at Birmingham
- Study coordinator: Wang, Weidong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.